OpenAI acquires Orchestra Bio to expand drug development tools
Key Facts
OpenAI confirmed its acquisition of Orchestra Bio, adding tools for tracking the execution of drug development programs to its specialized life sciences models. The company said in its acquisition statement that it was combining Orchestra's team and technology with Rosalind models and research tools. The acquired company's technology allows scientists and program leaders to delegate the monitoring of studies and research campaigns to AI agents. Financial terms of the deal were not disclosed, according to Axios. Orchestra said in its announcement that it was joining OpenAI that it had launched 4 years ago to help biotechnology and pharmaceutical companies advance drug development programs.
OpenAI cited a manufacturing batch setback as an example of the operational problems Orchestra's tools target within drug development programs. Such a setback could delay a clinical trial, according to the company, requiring teams to identify the activities and timelines affected. The agents help track those dependencies and compare possible responses to the problem within the research program. Explaining the role of its technology, Orchestra said: "Agents can handle planning, coordination and analysis." Under the company's vision, scientists and program leaders would then focus on decisions requiring their expertise, while agents handle the program management tasks assigned to them.
The acquisition follows OpenAI's launch of GPT Rosalind, a model specializing in life sciences research, on 16 April 2026. At launch, the company estimated the average time from drug target discovery to regulatory approval for a new drug in the United States at about 10 to 15 years. Its research tools included a free life sciences plugin for Codex, connecting models to more than 50 scientific tools and data sources. The plugin allows models to connect to resources researchers use in their scientific work. In an update dated 11 September 2026, the company announced that the model had exited research preview and become available globally to eligible organizations through its trusted access program.
OpenAI also offers the Rosalind workspace in research preview through the ChatGPT app for testing guided scientific tasks. Researchers can adapt those tasks to their own data and methods, according to the company's explanation of the tool. In sequencing data analysis, Rosalind prepares a plan for the researcher to approve, then coordinates the selected tools and returns outputs that can be traced and reviewed. OpenAI has a collaboration with Moderna that began in early 2023, according to its statement on the partnership. Moderna developed a pilot project called Dose ID to serve as an assistant to the clinical study team in analyzing data and supporting clinical judgment and decision-making.
To make the tools available to researchers, Rosalind's academic plan gives eligible laboratories up to 30 seats on the standard Business plan. OpenAI set the cost of these seats at $0 per user per month during the support period. The free seats are available for up to 12 months, according to the plan's terms announced by the company. The academic program is currently limited to laboratories at U.S. universities. Global enterprise access to the Rosalind model is provided through the trusted access program for eligible organizations, according to the company's update, distinguishing its scope from that of the academic support reserved for U.S. laboratories.
In the competition for scientific research tools, Anthropic launched Claude Science, a platform for scientists, on 30 June 2026. The company said the platform uses a coordinating agent with more than 60 prebuilt skills and connectors. The disciplines served by these resources include genomics, proteomics and cheminformatics, according to the launch announcement. Anthropic included projects for the platform in its AI for Science program. It set the implementation period for those projects from 1 September to 1 December 2026, the end date of the program's announced period.